BEAM
Price
$19.80
Change
+$0.28 (+1.43%)
Updated
Apr 28 closing price
Capitalization
1.99B
14 days until earnings call
SYRE
Price
$14.67
Change
+$0.54 (+3.82%)
Updated
Apr 28 closing price
Capitalization
884.24M
9 days until earnings call
Ad is loading...

BEAM vs SYRE

Header iconBEAM vs SYRE Comparison
Open Charts BEAM vs SYREBanner chart's image
Beam Therapeutics
Price$19.80
Change+$0.28 (+1.43%)
Volume$1.27M
Capitalization1.99B
Spyre Therapeutics
Price$14.67
Change+$0.54 (+3.82%)
Volume$550.93K
Capitalization884.24M
BEAM vs SYRE Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. SYRE commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and SYRE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (BEAM: $19.80 vs. SYRE: $14.67)
Brand notoriety: BEAM and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 50% vs. SYRE: 72%
Market capitalization -- BEAM: $1.99B vs. SYRE: $884.24M
BEAM [@Biotechnology] is valued at $1.99B. SYRE’s [@Biotechnology] market capitalization is $884.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +8.55% price change this week, while SYRE (@Biotechnology) price change was +8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.21%. For the same industry, the average monthly price growth was +1.12%, and the average quarterly price growth was -9.09%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.99B) has a higher market cap than SYRE($884M). BEAM YTD gains are higher at: -21.290 vs. SYRE (-36.985). SYRE has higher annual earnings (EBITDA): -208.57M vs. BEAM (-383.98M). BEAM has more cash in the bank: 851M vs. SYRE (603M). SYRE has less debt than BEAM: SYRE (0) vs BEAM (161M). BEAM has higher revenues than SYRE: BEAM (63.5M) vs SYRE (0).
BEAMSYREBEAM / SYRE
Capitalization1.99B884M225%
EBITDA-383.98M-208.57M184%
Gain YTD-21.290-36.98558%
P/E RatioN/A1.68-
Revenue63.5M0-
Total Cash851M603M141%
Total Debt161M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
78
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMSYRE
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 25 days ago
85%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA284.9525.44
+9.80%
Tesla
GME27.460.38
+1.40%
GameStop Corp
SPY550.643.95
+0.72%
SPDR® S&P 500® ETF
AAPL209.280.91
+0.44%
Apple
BTC.X93754.840000-892.085940
-0.94%
Bitcoin cryptocurrency

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-3.22%
CRSP - BEAM
70%
Closely correlated
-2.15%
NTLA - BEAM
64%
Loosely correlated
+1.59%
RXRX - BEAM
62%
Loosely correlated
-0.35%
DNLI - BEAM
58%
Loosely correlated
+1.23%
VERV - BEAM
57%
Loosely correlated
-0.35%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+3.82%
BEAM - SYRE
53%
Loosely correlated
+1.43%
CGON - SYRE
52%
Loosely correlated
+25.03%
APGE - SYRE
51%
Loosely correlated
+2.55%
IMNM - SYRE
49%
Loosely correlated
+2.14%
ACLX - SYRE
49%
Loosely correlated
+1.32%
More